Skip to main content
Science / Explained
SERIES: The Drug LandscapeArticle 4 of 4
Semaglutide is 94% identical to GLP-1, and the other 6% changes everything

Semaglutide explained in one line: the molecule keeps most of native GLP-1's receptor-recognized shape, then adds targeted edits that extend duration from minutes to about a week.

Semaglutide explained: what changed from native GLP-1?

Native GLP-1 degrades quickly. Semaglutide keeps the core signal pattern but introduces specific molecular edits that protect against rapid enzymatic breakdown.

Why does the fatty-acid chain matter?

A C-18 fatty-acid chain helps albumin binding, which slows clearance and keeps the signal in circulation far longer than the native two-minute profile.

Those engineering choices stretch action toward weekly dosing while preserving receptor recognition.

What does the 94 percent similarity imply clinically?

Most of the molecule still maps to the known GLP-1 pathway. The key difference is durability and exposure window, not a completely new signal biology.

OneMoreThing

Three changes.That is it.Position 8: alanine replaced with aminoisobutyric acid to block DPP-4 from cutting the molecule.Position 34: lysine swapped for arginine.And a C-18 fatty acid chain bolted on so the molecule can hitchhike on albumin proteins in the blood.

Everything else is identical to what the gut produces after every meal.The revolution is in the 6%.Three precise edits turned a two-minute signal into a seven-day drug.The molecule is mostly nature.The engineering is mostly restraint.

← Previous
Ozempic, Mounjaro, and Retatrutide each hit a different set of receptors
References3 sources

How to read these sources

This article uses primary sources and reviews to separate mechanism, human evidence, and context.

MechanismCell and pathway logic
ReviewExpert synthesis
Human TrialStudies in people
Show 2 more source types
Official LabelRegulator documents
Public UpdateNews or announcements
  1. Mechanism

    Journal of Medicinal Chemistry

    American Chemical Society

    Lau, J., et al. · 2015 Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Read source

    Used Here For

    Documenting the chemical design work that produced semaglutide's once-weekly formulation.

    Good For

    Understanding the medicinal-chemistry design behind a long-acting GLP-1 analog.

    Not For

    Clinical efficacy or safety conclusions — this is chemistry, not trial data.

    J Med Chem 58(18):7370-7380
    PMID 26308095DOI 10.1021/acs.jmedchem.5b00726
  2. Review

    Frontiers in Endocrinology

    Frontiers Media

    Knudsen, L.B., & Lau, J. · 2019 The Discovery and Development of Liraglutide and Semaglutide. Read source

    Used Here For

    Tracing how liraglutide and semaglutide were discovered and developed into medicines.

    Good For

    Historical and design context on how GLP-1 drugs were engineered.

    Not For

    Current dosing guidance or head-to-head efficacy comparisons.

    Frontiers in Endocrinology, 10
    PMID 31031702DOI 10.3389/fendo.2019.00155
  3. Human TrialMassachusetts Medical Society

    Wilding, J.P.H., et al. · 2021 Once-Weekly Semaglutide in Adults with Overweight or Obesity. Read source

    Used Here For

    Providing the pivotal human trial results behind semaglutide's approval.

    Good For

    Human efficacy and safety data for semaglutide at approved trial doses.

    Not For

    Head-to-head comparison with other drugs or off-label dosing.

    New England Journal of Medicine, 384(11)
    PMID 33567185DOI 10.1056/NEJMoa2032183